Original research
by
McGee, Meghan et al
Release Date
2023
Geography
Canada
Language of Resource
English
Full Text Available
Yes
Open Access / OK to Reproduce
Yes
Peer Reviewed
Yes
Objective
To investigate excess costs of buprenorphine-naloxone due to unmerited market exclusivity (no legal patent or data protection) in Canada.
Findings/Key points
If buprenorphine-naloxone cost $0.61 CAD (mean cost after the third generic entered) instead of $1.21 CAD per mg during the pre-generics period, public payers in British Columbia could have saved $5,016,220 CAD between 2011 and 2015. Unmerited 6 years of market exclusivity for brand-name buprenorphine-naloxone in Canada resulted in substantial excess costs.
Design/methods
Interrupted time series examining cost changes before and after formularies listed generics
Keywords
Policy/Regulatory
Barriers and enablers
Substitution/OAT
